34 results about "Chrysoeriol" patented technology

A cannabis-based flavonoid pharmaceutical composition including any one or more selected from among the group of Cannflavin A, Cannflavin B. Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside and their derivatives selected from among the group of Geraldol, Rhamnetin, Isorhamnetin, Rhamnazin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and histone acetylases. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include but are not limited to brain, breast, colon, renal liver, lung, pancreatic, pigmented villonodular synovitis, prostate, leukemia, melanomam, tenosynovial giant cell tumor, as well as any other cancers that overexpress the oncogenic factors inhibited, by the cannabis flavonoids or their derivatives herein identified.

The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin, (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain diseases of the CNS system and related disorders.

The invention provides O-methyltransferase participating in citrus peel flavone synthesis and a coding gene and application thereof. The expression level of CitOMT1 is positively correlated with the accumulation of polymethoxylated flavones in a fruit development process of Citrus reticulata cv. Suavissima; in vitro enzyme activity assays indicate that the O-methyltransferase can be applied to catalyze specific site methylation of flavones, in particular to catalyze quercetin to produce quercetin 3',4' dimethyl ester, catalyze luteolin to produce chrysoeriol, catalyze eriodictyol to produce hesperidin and homoeriodictyol, catalyze baicalein to produce oroxylin A, and catalyze 7,8-dihydroxyflavone to produce 7-hydroxy-8-methoxy flavone. The enzyme activity assays have simple reaction conditions, do not require additional metal ions, and have high application value and research prospects.

The invention provides novel application of parthenolide, luteolin, chrysoeriol and ginsenoside Rg3, and specifically relates to preparation of the compounds or derivatives of the compounds in preparation of drugs for preventing and / or treating drug-resistant BRAF (V600E) mutant-type tumors. It is found that proliferation of tumor cells resistant to BRAF (V600E)-targeted drugs can be inhibited through parthenolide, luteolin, chrysoeriol and ginsenoside Rg3, the tumor cells include inherent and acquired tolerant tumor cells, and growth of tumors is inhibited. It is shown through results that parthenolide, luteolin, chrysoeriol and ginsenoside Rg3 have the potential to be developed as the safe and effective drugs for treating the drug-resistant BRAF (V600E) mutant-type tumors.

The invention discloses chrysoeriol-7-O-beta-D-butyl glucuronate. The structural formula of the chrysoeriol-7-O-beta-D-butyl glucuronate is shown in the description. The invention also discloses an extraction method of the chrysoeriol-7-O-beta-D-butyl glucuronate and application of the chrysoeriol-7-O-beta-D-butyl glucuronate in preparation of antioxidant drugs, antioxidant cosmetics, hypoglycemic drugs or anti-tumor drugs.

The invention discloses a drug composition for preventing and / or treating diseases caused by fat deposition. The drug composition comprises acacetin and synergistic compounds of the acacetin, whereinthe synergistic compounds include one or more of jaceosidin, kaempferol, chrysoeriol, quercetin, apigenin, hispidulin, luteolin, quercitrin, rutin, isorhamnetin and genkwanin. The acacetin can obviously inhibit 3T3-L1 preadipocyte differentiation, when the acacetin is combined with the synergistic compounds in use, the inhibition effect of the acacetin can be obviously enhanced, the use amount ofthe acacetin and the synergistic compounds can be obviously reduced, and the cost of the preparation is reduced. The drug composition can be used for treating and preventing the diseases caused by fatdeposition.

The invention provides a compounding method for chrysoeriol, solving the problems of operation complexity and low yield in the prior art. The compounding method includes mixing anhydrous phloroglucinol with 3-methoxy-4-hydroxy-benzoyl ethyl acetate and dimethyl sulfoxide, heating and stirring the mixture, stopping heating to remove vacuum after complete vacuum reaction, cooling the mixture to roomtemperature, adding water, and performing stirring and filtering to obtain a crude chrysoeriol solid; subjecting the crude chrysoeriol solid to recrystallization by ethyl alcohol, and performing decoloration, concentration, recrystallization, filtration and drying to obtain the refined chrysoeriol. The compounding method has the advantages of simple and convenient procedure, simplicity in post-treatment, high yield of the whole process and applicability to large-scale industrial production.

The present invention relates to a method for isolating flavonoids such as cochlioquinone or chrysoeriol from a rice plant inoculated with a whitebacked planthopper. The method of the present invention, for example, facilitates not only the fast production of flavonoids such as cochlioquinone or chrysoeriol but also the mass-production of flavonoids such as cochlioquinone or chrysoeriol with high efficiency in addition to the advantage of saving costs. Therefore the method of the present invention can be effectively used for the production of flavonoids such as cochlioquinone or chrysoeriol and also be used in various fields using the same.

The invention discloses a chrysoeriol-7-O-beta-D-ethyl glucuronate. The structural formula of the chrysoeriol-7-O-beta-D-ethyl glucuronate is A. The invention also discloses an extraction method of the chrysoeriol-7-O-beta-D-ethyl glucuronate and application of the chrysoeriol-7-O-beta-D-ethyl glucuronate to preparing antioxidant drugs, antioxidant cosmetics, hypoglycemic drugs and anti-tumor drugs.

The invention discloses a chrysoeriol-7-O-beta-D glucuronic acid methyl ester. The structural formula of the chrysoeriol-7-O-beta-D glucuronic acid methyl ester is disclosed in the following diagram. The invention also discloses an extraction method for the chrysoeriol-7-O-beta-D glucuronic acid methyl ester and the application of the chrysoeriol-7-O-beta-D glucuronic acid methyl ester for preparing antioxidant medicines, antioxidant cosmetics, hypoglycemic drugs or antitumor drugs.

The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin and Flavocannabiside or their synthases, for the prevention and treatment of certain ocular diseases and related disorders.

The invention relates to a method for separating and purifying three flavonoid glycoside type components from stems and leaves of trichosanthes kirilowii. The stems and the leaves of the trichosanthes kirilowii are taken as raw materials, and the method comprises the following steps: (1) preparing a crude extract of the stems and the leaves of the trichosanthes kirilowii; (2) extracting; (3) performing semi-preparation type high performance liquid chromatography separation and purification: performing separation and purification on an ethyl acetate part by semi-preparation type high performance liquid chromatography, wherein a mobile phase is methanol-water, and three high-purity flavonoid glycoside type components, namely luteolin-7-O-beta-glucoside, apigenin-7-O-beta-glucoside and chrysoeriol-7-O-beta-glucoside are respectively obtained. The process flow is green and environment-friendly, has no serious harm to an environment and is low in comprehensive cost.

The invention relates to novel application of chrysoeriol-7-beta-D-glucose-2''-sulfate shown in a formula (1) in preparation of herpes simplex virus resistant drug. The chrysoeriol-7-beta-D-glucose-2''-sulfate has no remarkable toxicity on a host Vero cell, the maximum toxicity-free concentration (TC0) of the chrysoeriol-7-beta-D-glucose-2''-sulfate to the Vero cell is more than 260mu g / mL, the inhibiting concentration (IC50) of the chrysoeriol-7-beta-D-glucose-2''-sulfate to HSV-1 (Herpes Simplex Virus) under a combined action manner is 3.772mu g / mL, the IC50 of the chrysoeriol-7-beta-D-glucose-2''-sulfate to the HSV-1 under a direct virus inactivating action manner is 0.084mu g / mL, the IC50 of the chrysoeriol-7-beta-D-glucose-2''-sulfate to the HSV-1 under an adsorption inhibiting action manner is 14.5mu g / mL, and the IC50 of the chrysoeriol-7-beta-D-glucose-2''-sulfate to the HSV-1 under a transfer inhibiting action manner is 12.06mu g / mL. The chrysoeriol-7-beta-D-glucose-2''-sulfate ensures that the virus cannot normally adsorb and penetrate in the cell through direct virus inactivation on the basis of preliminary guess, thereby blocking the HSV-1 infection outside the cell.

The invention provides an elsholtzia extract, and a preparation method and an application thereof, and belongs to the technical field of plant extracts. The elsholtzia extract comprises 0.62-3.78 mg / g of apigenin, 2.19-4.44 mg / g of baicalein-7-methyl ether, 30-120 [mu] g / g of quercetin, 0.79-3.29 mg / g of kaempferol, 34-120 [mu] g / g of luteolin and 4.22-6.67 [mu] g / g of chrysoeriol. The elsholtzia extract is prepared by a percolation assisted enzymolysis process. The elsholtzia extract can achieve a whitening effect by inhibiting the activity of tyrosinase.

The invention provides a preparation method of chrysoeriol. A high-purity chrysoeriol product is obtained by the steps of alkali extraction and water precipitation, organic solvent extraction, membrane concentration, macroporous resin adsorption, and the like. In a membrane separation process, not only the product purity is improved, but also the damage to resin is alleviated, and the service life of the resin is prolonged; and by adopting crystallization and recrystallization, the purification efficiency is high. The whole preparation process has the advantages that requirements on environment and equipment are low, extraction and separation time is short, purity is high and the preparation method is simple and easy to operate.

The invention discloses application of eriodictyol in preparation of a medicine for treating vaginitis, and experiments prove that eriodictyol has an inhibition effect on fungi and bacteria causing vaginitis.

The invention belongs to the technical field of biological health-care products, and particularly relates to an intestinal exclusive active ginseng and walnut peptide composition for improving human circulation. The intestinal exclusive active ginseng and walnut peptide composition is prepared from the following raw materials in parts by weight: 2-10 parts of ginseng peptide, 5-15 parts of walnut peptide, 14-20 parts of soybean peptide, 6-10 parts of peanut peptide, 6-12 parts of a fructus momordicae extract, 8-12 parts of asparaginic acid, 5-15 parts of vitamin A, 5-15 parts of chrysoeriol, 0.2-0.8 part of a sweetening agent and 0.3-0.5 part of beta-amylase. Through scientific compatibility of the raw materials, the intestinal exclusive active ginseng and walnut peptide composition has obvious effects on symptoms, such as frequent constipation, dull skin colour, stains, abdominal distension and pain, haemorrhoids and ozostomia, and has the effects of supplementing cell nutrition, enhancing the immune function, protecting the liver, moistening and repairing the inner wall of the gastrointestinal tract and regulating heart and cerebral vessels and sleep.

The invention discloses an anti-stroke pharmaceutical composition and application thereof, and belongs to the technical field of medicines. The pharmaceutical composition comprises active compositions and pharmaceutically-acceptable auxiliary materials, and the active compositions comprise the following components: (1) racemic amlodipine and levogyrate amlodipine or pharmaceutically-acceptable salts; and (2) chrysoeriol. Chrysoeriol combined with amlodipine has the effect of synergically resisting brain stroke, and the pharmaceutical composition prepared from chrysoeriol and amlodipine is applicable to prevent brain tissue from being damaged after brain stroke happens.

The invention belongs to the technical field of medicines and particularly relates to methoxy-7-luteolin and preparation method and application thereof. The preparation method of the methoxy-7-luteolin includes: adopting 95% ethyl alcohol for reflux extraction from herba leonuri, sequentially subjecting concentrated extract liquid to extraction with petroleum ether, ethyl acetate and normal butanol, and eluting to obtain a compound namely the methoxy-7-luteolin. A pharmaceutical composition containing methoxy-7-luteolin is used for ovulation failure caused by breast cancers, hyperplasia of mammary glands and polycystic ovarian syndromes. According to researches, methoxy-7-luteolin has an evident inhibition effect on in-vitro estradiol synthesis ratio, is free of evident cytotoxicity and has a curative effect on ovulation failure caused by breast cancers, hyperplasia of mammary glands and polycystic ovarian syndromes.

The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin and Flavocannabiside or their synthases, for the prevention and treatment of certain ocular diseases and related disorders.

The invention provides a lavender composition, a preparation method and application thereof, and belongs to the technical field of plant extracts, the lavender composition comprises the following components: 0.59 to 3.60 mg / g of apigenin, 2.08 to 4.22 mg / g of baicalein-7-methyl ether, 28.57 to 114.28 [mu] g / g of quercetin, 0.75 to 3.13 mg / g of kaempferol, 32.38 to 114.28 [mu] g / g of luteolin, 4.02 to 6.35 [mu] g / g of chrysoeriol, and 47.6 mg / g of lavender essential oil. The lavender composition shows prominent tyrosinase inhibition activity when the concentration is 0.2 mg / ml, the tyrosinase inhibition activity is far higher than 1 + 1 activity of the elsholtzia extract and the lavender essential oil, and the whitening effect can be achieved by inhibiting the tyrosinase activity.

The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin, (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain diseases of the CNS system and related disorders.

The invention discloses chrysoeriol-7-O-beta-D-butyl glucuronate. The structural formula of the chrysoeriol-7-O-beta-D-butyl glucuronate is shown in the description. The invention also discloses an extraction method of the chrysoeriol-7-O-beta-D-butyl glucuronate and application of the chrysoeriol-7-O-beta-D-butyl glucuronate in preparation of antioxidant drugs, antioxidant cosmetics, hypoglycemic drugs or anti-tumor drugs.

The invention provides a wild buckwheat rhizome extract as well as a preparation method and application thereof, and belongs to the technical field of plant extracts, the wild buckwheat rhizome extract comprises the following components: 4.19 to 10.44 mg / g of epicatechin, 2.48 to 7.79 mg / g of proanthocyanidin B4, 2.05 to 9.98 mg / g of catechin, 2.00 to 4.67 mg / g of gallic acid, 81 to 128 [mu] g / g of proanthocyanidin B and 1.97 to 10.37 [mu] g / g of chrysoeriol. The extract is prepared by a percolation-assisted enzymolysis process. The rhizoma fagopyri dibotryis extract can achieve a whitening effect by inhibiting the activity of tyrosinase.

The invention relates to a plant flavone methyltransferase protein as well as an encoding gene and application thereof. Enzyme activity experiment of IiOMT1 protein encoded by an IiOMT1 gene shows that transgenosis experiment that the IiOMT1 gene is introduced into isatis indigotica shows that contents of 3'-O-methylflavones such as chrysoeriol and / or isoscoparin in a plant, namely transgenic isatis indigotica in which the IiOMT1 gene is expressed, can be increased when being compared with those in receptor isatis indigotica, it means that the IiOMT1 gene is a gene related to the contents of the 3'-O-methylflavones such as chrysoeriol and / or isoscoparin in the plant, the IiOMT1 gene and an encoding gene thereof can be adopted to increase the contents of the 3'-O-methylflavones such as chrysoeriol and / or isoscoparin in the plant.

An embodiment of the invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected, from among the group of Apigenin, Cannflavin. A. Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and BCL-2. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include brain, breast, colon, renal, liver, lung, pancreatic, prostate, leukemia, melanoma as well as any other cancers that overexpress the oncogenic factors inhibited by the cannabis flavonoids identified herein.

The invention discloses a chrysoeriol-7-O-beta-D-ethyl glucuronate. The structural formula of the chrysoeriol-7-O-beta-D-ethyl glucuronate is A. The invention also discloses an extraction method of the chrysoeriol-7-O-beta-D-ethyl glucuronate and application of the chrysoeriol-7-O-beta-D-ethyl glucuronate to preparing antioxidant drugs, antioxidant cosmetics, hypoglycemic drugs and anti-tumor drugs.